Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AstraZeneca releases peer-reviewed data for its COVID-19 vaccine

By Brian Buntz | December 8, 2020

AstraZeneca (LON:AZN) and its collaborators at the University of Oxford have published data related to their ChAdOx1 nCoV-19 vaccine against the novel coronavirus in the Lancet, becoming the first vaccine developers to publish full Phase 3 results in a peer-reviewed journal. 

The efficacy rate of 62.1% achieved in clinical trial participants receiving two full doses of the vaccine exceeds FDA’s baseline requirement of 50% efficacy. But the figure is considerably less than the 90% efficacy the COVID-19 vaccines from Pfizer (NYSE:PFE) and Moderna (NYSE:MRNA) promise, both of which also require two doses.   

The overall efficacy was higher — approximately 90% — in vaccine recipients who received a half dose followed by a full dose. The low-dose/standard-dose regimen, however, was 59% effective at protecting against asymptomatic COVID-19 infection. 

Nevertheless, the data “provide some hope that COVID-19 vaccines might be able to interrupt some asymptomatic transmission,” the study authors concluded. 

The vaccine was mostly well-tolerated in patients, with 175 experiencing severe adverse events out of a patient pool of 11,636. Of that total, 84 were in the vaccine group. The remainder received a placebo. 

At one point during the Phase 3 study, the company halted trials around the world after a U.K. participant fell ill with neurological symptoms. The company later concluded that that adverse event was unrelated to the vaccine.  

But according to the New York Times, AstraZeneca initially failed to disclose that news to the FDA, potentially damaging its relationship with regulators. 

The vaccine, however, offers advantages in terms of its low cost and simple storage requirements. 

Regulatory agencies in the U.K., India and other countries could authorize emergency use of the vaccine in the near future. 


Filed Under: clinical trials, Drug Discovery, Uncategorized
Tagged With: AstraZeneca plc, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, FDA, Moderna, Pfizer
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Comments

  1. ed scott says

    January 11, 2021 at 8:01 pm

    I am trying to find out if Astra Zenanca have published any data on the placebo broup in their covid vaccine trials. Specifically, I am trying to understand how many people developed covid and how many didn’t in both groups (placebo and the test). The other major vaccine producers have published results via the New England Medical Journey and it makes interesting reading. Astonishing is how few people developed covid symptoms in the placebo group. Well below national averages in both the UK and US. The number of people who died in the trials is mercifully low (1 in total I think).
    So can we draw comparisons from the trial datasets and the national data sets? Clearly not, otherwise the trial death toll would have been alarmingly higher.

Related Articles Read More >

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
From 1.5% to 5.9%: Deloitte digs into what’s fueling Big Pharma’s R&D IRR climb
Recce targets A$15.8M to advance anti-infectives into Phase 3 trials
Vial of Steroid injection with a syringe on black table and stainless steel background.
The true cost of steroid-toxicity 
3D illustration of Palm painful - skeleton x-ray, medical concept.
Q&A: AnaptysBio’s CMO on rosnilimab’s ‘compelling’ phase 2b RA results
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE